KEYNOTE-052: Updated Findings on First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer

June 2-6, 2017; Chicago, Illinois
ORR increased from previous report with longer follow-up and 18-gene GEP score significantly associated with response.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.38 MB
Released: June 8, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in androgen deprivation therapy for prostate cancer

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: October 6, 2021 Expired: October 5, 2022

Health-related quality of life, pain, safety outcomes from VISION trial of 177Lu-PSMA-617 in men with mCRPC presented at the 2021 ESMO Congress, reported by Clinical Care Options (CCO)

Released: September 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue